01—Abstract
Summary
Summary of the 8-K filed October 21, 2026. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories (ABT) reported strong third-quarter 2026 results, with total reported sales increasing by 14.5%a and comparable sales growing by 7.0%.
The company reaffirms its full-year 2026 adjusted diluted earnings per share (EPS) guidance of $5.50 to $5.55b, tightening the range. This performance was driven by broad-based growth across its key business segments, including Diagnostics and Medical Devices, with notable contributions from new product approvals and market expansions.
The report also details significant progress in product innovation and regulatory approvals, including the FDA approval of Libre® Duo, a dual glucose-ketone sensor, and the CE Mark for the Amulet 360™ Left Atrial Appendage Occluder. These advancements, coupled with reaffirmed financial guidance, suggest continued positive momentum for Abbott Laboratories heading into the final quarter of the year.
02—Key points
Key Highlights
- Third-quarter reported sales grew 14.5%, reaching $13,013 million, with comparable sales up 7.0% to $13,053 million.
- Full-year 2026 adjusted diluted EPS guidance is reaffirmed and tightened to a range of $5.50 to $5.55.
- Significant new product approvals bolster the innovation pipeline, including Libre® Duo (dual glucose-ketone sensor) and Amulet 360™ LAA Occluder.
- The Diagnostics segment showed robust reported sales growth of 46.7%, driven by the integration of Exact Sciences.
- Medical Devices segment reported sales increased 6.9%, with strong performance in Rhythm Management and Electrophysiology.
- The company declared its 411th consecutive quarterly dividend of $0.63 per share, underscoring its commitment to returning capital to shareholders.
- Abbott projects full-year 2026 comparable sales growth of approximately 6.0%.
03—Questions
Frequently Asked Questions
What were the key drivers of Abbott's third-quarter sales growth?
Abbott's third-quarter sales growth was driven by a broad-based performance across its business segments. The Diagnostics segment saw a significant increase of 46.7% in reported sales, largely due to the integration of Exact Sciences. The Medical Devices segment also showed solid growth of 6.9%, led by double-digit increases in Electrophysiology and Rhythm Management. The Nutrition and Established Pharmaceuticals segments also contributed positively to overall comparable sales growth.
How did Abbott's earnings per share (EPS) perform in the third quarter?
In the third quarter of 2026, Abbott reported GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42. The adjusted EPS excludes specified items, which include significant charges like intangible amortization, legal settlements, and acquisition-related expenses. The company reaffirmed its full-year 2026 adjusted diluted EPS guidance, indicating confidence in its ongoing operational performance.
What notable product approvals or advancements were mentioned in the filing?
The filing highlighted several key product advancements. These include the U.S. FDA approval for Libre® Duo, the world's first dual glucose-ketone biowearable sensor, the CE Mark for the Amulet 360™ Left Atrial Appendage (LAA) Occluder designed to reduce stroke risk in atrial fibrillation patients, and FDA approval for SimpleScreen™ CRC, a blood-based colorectal cancer screening test.
Does Abbott provide forward-looking financial guidance, and what are the key projections?
Yes, Abbott reaffirmed its full-year 2026 adjusted diluted EPS guidance to be between $5.50 and $5.55. They also project full-year 2026 comparable sales growth to be approximately 6.0%. The company also provided guidance for fourth-quarter 2026 adjusted diluted EPS, projecting it to be between $1.62 and $1.67. Abbott notes that it does not provide forward-looking GAAP measures due to the unpredictability of certain items affecting GAAP results.
04—Continue